



Company Announcement

6 April 2010

Status regarding Novo Nordisk's holding of its own shares (31 March 2010)

In continuation of the company's announcement dated 2 February 2010 concerning a planned share repurchase programme, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 March 2010 owned 33,981,298 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 33,981,298 or 5.48% of the total share capital.

In the first quarter of 2010 a total of 3,710,000 B shares were repurchased, and 1,866,647 B shares were disposed of to employees in connection with employee incentive programmes.

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

For further information please contact:

Media:

Outside North America:
Elin K Hansen
Tel: (+45) 4442 3450
ekh@novonordisk.com

In North America:
Sean Clements
Tel: (+1) 609 514 8316
secl@novonordisk.com

Investors:

Outside North America:
Klaus Bülow Davidsen
Tel: (+45) 4442 3176
klda@novonordisk.com

Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com

In North America:
Hans Rommer
Tel: (+1) 609 919 7937
hrrm@novonordisk.com